GUIDEWIRE
Guidewire (NYSE: GWRE) today announced that it has opened its new EMEA headquarters 10 years after the company opened its first office in Dublin. Based in Blanchardstown, the new office building occupies 85,000ft² and is evidence of Guidewire’s continued commitment to Ireland and its customers across Europe. Adapting to the new world of work, Guidewire is offering employees fully remote and hyperflexible working practices. As well as providing employees with a state-of-the-art work environment, the office also includes an executive briefing centre for its customer and partner community across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006033/en/
Since 2011, Guidewire’s Dublin base has grown to become the company’s largest employee community in Europe and outside of the USA, including a diverse range of 35+ nationalities. Guidewire anticipates scaling headcount by about 150 new recruits to around 600 staff over the next two to three years and is actively hiring across a range of positions, from entry-level graduate roles to business analysts, cloud operations, consulting managers, engineering, HR & Recruitment, project managers, specialist cloud transition roles, and technology consultants.
Since 2016 Guidewire Dublin has made the top 20 in the Great Place to Work, including 10th place in Ireland’s Best Workplaces 2021 for best large company.
“This is an exciting moment for Guidewire in Ireland as we open our new EMEA HQ, reflecting the enormous contribution of our team to the Guidewire corporate and customer community,” said Niall Lalor, Ireland country manager, Guidewire. “As the company has grown and evolved over the past 10 years in Ireland, I’m hugely proud that we have retained our strong sense of identity and close-knit culture throughout. We’ve still only scratched the surface and look forward to growing our talented team even more across the country, with Guidewire in Dublin well placed as a hub for innovation that supports our business both in EMEA and globally.”
The Irish operations include Customer & Cloud Operations, Delivery Services, and Product Development, with teams that have spearheaded Guidewire’s digital products, created specific local solutions for European customers, as well as managed the implementations and support of the company’s first cloud customers. The siting of the cloud team in Dublin also takes advantage of access to top new graduates from Ireland, the wider European Union, and beyond.
“Ireland has been central to Guidewire’s international growth over the past 10 years,” said Mike Rosenbaum, chief executive officer, Guidewire. “It’s nothing new to say that the world has witnessed extraordinary changes over the past two years and the insurance industry is no exception. Guidewire continues to be an indispensable partner to our 450+ customers around the world. Guidewire aspires to design, build, and run a mission critical cloud service, and our team in Ireland is critical to making this a reality.”
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, said “I’m so pleased Guidewire has chosen Blanchardstown for its new EMEA headquarters. Guidewire is a leading player in the software industry and this expansion, which will create an additional 150 highly skilled jobs, demonstrates the company’s continued commitment to Ireland after 10 years. I wish the team every success with their expansion plans.”
Commenting on the news Mary Buckley, Executive Director, IDA Ireland, said “Today’s announcement demonstrates Guidewire’s continued confidence in the availability of a highly skilled and talented workforce in Ireland to further support its evolution and to deliver on its strategic corporate goals. I wish the team continued success in their new office building and offer the company the ongoing support of IDA Ireland.”
Further details are available at: https://careers.guidewire.com/location/dublin
Dublin office video:
https://players.brightcove.net/929656735001/41G8Cuaute_default/index.html?videoId=6300984518001
About Guidewire
Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 450 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localisation, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom